Facioscapulohumeral muscular dystrophy therapy (Avidity Biosciences)

N/A

Report date: 2022/02/08 10:39:50
NME

Base Information

Drug NameFacioscapulohumeral muscular dystrophy therapy (Avidity Biosciences)
Drug Alias NameAOC-FSHD
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interference
TargetsUpdating
Therapy Area/IndicationsMuscular Dystrophy, Facioscapulohumeral
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAvidity Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesAvidity Biosciences Inc
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Facioscapulohumeral
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A